{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:21:38Z","timestamp":1790684498179,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2020CXGC010503"],"award-info":[{"award-number":["2020CXGC010503"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003584"],"award-info":[{"award-number":["82003584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103983"],"award-info":[{"award-number":["82103983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020QH343"],"award-info":[{"award-number":["ZR2020QH343"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3008000-842112022"],"award-info":[{"award-number":["3008000-842112022"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bmcl.2022.128797","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T11:17:52Z","timestamp":1652527072000},"page":"128797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Comparison of three zinc binding groups for HDAC inhibitors \u2013 A potency, selectivity and enzymatic kinetics study"],"prefix":"10.1016","volume":"70","author":[{"given":"Kairui","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"James Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128797_b0005","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","article-title":"Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases","volume":"59","author":"Porter","year":"2019","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmcl.2022.128797_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1517\/14728222.2013.729042","article-title":"Targeting class I histone deacetylases in cancer therapy","volume":"17","author":"Delcuve","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmcl.2022.128797_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21238943","article-title":"Inhibition of HDAC enzymes contributes to differential expression of pro-inflammatory proteins in the TLR-4 signaling cascade","volume":"21","author":"Weiss","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2022.128797_b0025","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/med.21701","article-title":"Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities","volume":"40","author":"Rodrigues","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2022.128797_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117278","article-title":"Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders","volume":"243","author":"Gupta","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2022.128797_b0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/icb.2011.95","article-title":"HDAC inhibitors in HIV","volume":"90","author":"Wightman","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.bmcl.2022.128797_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.2000.5080","article-title":"The human histone deacetylase family","volume":"262","author":"Gray","year":"2001","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bmcl.2022.128797_b0045","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2022.128797_b0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1358\/dot.2009.45.11.1437052","article-title":"Romidepsin for the treatment of cutaneous T-cell lymphoma","volume":"45","author":"Campas-Moya","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.bmcl.2022.128797_b0060","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2022.128797_b0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.bmcl.2022.128797_b0075","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/ci500762z","article-title":"Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: A case study using histone deacetylase 8","volume":"55","author":"Hou","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2022.128797_b0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-012-1940-9","article-title":"Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients","volume":"70","author":"Clive","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128797_b0090","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128797_b0095","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0100","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/acs.jmedchem.8b00136","article-title":"Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status","volume":"61","author":"Li","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0105","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10408347.2014.881250","article-title":"Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis","volume":"45","author":"Olaru","year":"2015","journal-title":"Crit Rev Anal Chem"},{"key":"10.1016\/j.bmcl.2022.128797_b0115","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmcl.2022.128797_b0120","first-page":"1","article-title":"Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem Anal"},{"key":"10.1016\/j.bmcl.2022.128797_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ph14101032","article-title":"Mechanistic insights into binding of ligands with thiazolidinedione warhead to human histone deacetylase 4","volume":"14","author":"Schweipert","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2022.128797_b0130","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:41Z","timestamp":1760773481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22002736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":26,"alternative-id":["S0960894X22002736"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128797","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of three zinc binding groups for HDAC inhibitors \u2013 A potency, selectivity and enzymatic kinetics study","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128797"}}